E-mail: bd@sidmexinovia.com
Telefone: +918866862020
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Empasov 25mg Tablet
Manufacturer/Marketed By : CIPLA LTD
$1.50 $1.36
Empasov 25mg Tablet is an oral medication belonging to the pharmacological class of sodium-glucose co-transporter-2 (SGLT2) inhibitors. It is primarily used for managing type 2 diabetes mellitus by improving glycemic...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
EMPAGLIFLOZIN
Active Pharmaceutical Ingredient
Empasov 25mg Tablet
US$ 1,50
US$ 1,36
Empasov 25mg Tablet is an oral medication belonging to the pharmacological class of sodium-glucose co-transporter-2 (SGLT2) inhibitors. It is primarily used for managing type 2 diabetes mellitus by improving glycemic control. Additionally, it may help reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Empasov 25mg Tablet is available in tablet form and is typically administered once daily, with or without food. Empasov 25mg Tablet works by blocking SGLT2 proteins in the kidneys, preventing glucose reabsorption and promoting glucose excretion through urine. While Empasov 25mg Tablet is generally considered safe for most individuals, but caution should be exercised in patients with renal impairment, those with a history of diabetic ketoacidosis, or individuals with hypersensitivity to the active constituent. It is contraindicated during pregnancy and breastfeeding unless specifically advised by a healthcare provider.
Active Pharmaceutical Ingredient
Usos
• Management of type 2 diabetes mellitus to improve glycemic control.
• Reduction of cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease.
• Potential benefits in managing heart failure and chronic kidney disease (as recommended by healthcare professionals).
Benefícios
Empasov 25mg Tablet works by inhibiting the SGLT2 proteins located in the proximal renal tubules of the kidneys. By blocking these proteins, it reduces glucose reabsorption and promotes the excretion of excess glucose through urine. This mechanism helps lower blood sugar levels effectively and provides cardiovascular and renal protective benefits. Additionally, Empasov 25mg Tablet may help reduce body weight and blood pressure as secondary effects, which are beneficial for patients with type 2 diabetes.
Efeitos colaterais
Common Side Effects
Efeitos colaterais mais comuns
• Severe hypoglycemia (when combined with insulin or insulin secretagogues)
• Ketoacidosis (rare but serious)
• Acute kidney injury
• Severe allergic reactions (rash, itching, swelling)
Efeitos colaterais comuns
• Increased urination
• Thirst
• Dizziness
• Genital yeast infections (especially in women)
• Urinary tract infections
Como usar
Empasov 25mg Tablet is available in tablet form, typically taken once daily, with or without food. Swallow the tablet whole with water. Adhere to the prescribed dosage as instructed by your healthcare provider. Do not alter or discontinue the medication without professional guidance.
Conselhos de segurança
• Breast Feeding: It is unknown whether Empasov 25mg Tablet passes into breast milk. Avoid use or consult a healthcare provider for advice.
• Alcohol: Consumption of alcohol may increase the risk of dehydration and affect blood sugar control.
• Liver: Patients with severe liver impairment should use Empasov 25mg Tablet with caution and under medical supervision.
• Lungs: Empasov 25mg Tablet does not have known adverse effects on lung function.
• Driving: Patients experiencing dizziness or fatigue should avoid driving until symptoms subside.
• Pregnancy: Empasov 25mg Tablet should be avoided during pregnancy unless prescribed by a healthcare provider. Limited data suggests potential harm to the developing fetus.
Isenção de responsabilidade
A Sidmex Inovia se esforça para fornecer informações precisas e confiáveis; no entanto, todo o conteúdo deste site, incluindo descrições e composições de produtos, tem caráter meramente informativo e não deve ser considerado um substituto para aconselhamento, diagnóstico ou tratamento médico profissional.
Recomenda-se aos usuários que consultem um profissional de saúde qualificado antes de tomar qualquer decisão médica. As informações fornecidas não devem ser usadas para autodiagnóstico ou automedicação.
Todos os produtos listados destinam-se estritamente a consultas B2B e em grandes quantidades. A Sidmex Inovia não promove o uso direto pelo consumidor e visa apoiar, e não substituir, a relação entre o profissional de saúde e o paciente.
Os nomes de produtos, marcas comerciais e marcas pertencem aos seus respectivos proprietários, e seu uso não implica qualquer afiliação ou endosso. A Sidmex Inovia não se responsabiliza por quaisquer consequências decorrentes do uso das informações fornecidas neste site.